Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

NCT00485563 is registered in ClinicalTrials.gov with Endocyte as lead sponsor.

NCT NCT00485563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00485563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Lead sponsor
Endocyte
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2007
Completion date
March 31, 2009
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma